Association of lipid-lowering drug targets with risk of cutaneous melanoma: A mendelian randomization study

Melanoma proliferation is partly attributed to dysregulated lipid metabolism. The effectiveness of lipidlowering drugs in combating cutaneous melanoma (CM) is a subject of ongoing debate in both in vitro and clinical studies.